New York, NY based Immune Pharmaceuticals Inc. (IMNP) applies a personalized approach to treating and, developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, Bertilimumab, is in clinical development for moderate to severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. The Company recently expanded its portfolio in immuno-dermatology, topical nano-formulated Cyclosporine A (CsA) for the treatment of psoriasis and atopic dermatitis. Immune’s pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics. Other indications planned for development include Crohn’s disease, severe asthma and NASH (liver disease).
Immune Pharmaceuticals, Inc. (IMNP) recently announced that its Chief Executive Officer, Dr. Daniel Teper, has established a stock trading plan with respect to the purchases of up to an aggregate of $250,000 of shares of Immune common stock in accordance with Rule 10b5-1 under the Exchange Act and other applicable federal securities laws and regulations adopted by the Securities and Exchange Commission. The transactions under this plan will be disclosed publicly through Form 4 filings with the Securities and Exchange Commission.
Dr. Teper had recently purchased 7,569 shares of Immune common stock at $1.29 per share on September 1, 2015. More recently, two members of the Board of Directors of Immune purchased 50,000 shares of Immune common stock at $1.47 per share and 50,000 shares of Immune common stock at $1.48 per share respectively. These purchases by Dr. Teper and the members of the Board of Directors, respectively, are reflected in Forms 4 Statement of Change in Beneficial Ownership of Securities filed with the Securities and Exchange Commission.
Immune also announced recently that Boris Shor, Ph.D. has joined the company as Executive Director, R&D and Scientific Partnerships. Dr. Shor will be establishing and directing a new immunology research laboratory at the Alexandria Center for Life Science in New York City for Immune, at the company’s headquarters. He will lead translational research efforts to support the development of the company’s lead clinical stage candidate, bertilimumab, as well as the discovery and development of pipeline drugs utilizing NanomAbs®, antibody nano-conjugates for the targeted delivery of cancer drugs. Dr. Shor brings more than a decade of pharma industry experience in oncology drug discovery, early development and translational research, with expertise in both biologics and small molecule therapeutics. He joins Immune from the Pfizer Oncology Research Unit where he led internal and external collaboration project teams to develop novel antibody-drug conjugates (ADCs) for the treatment of cancer. Most recently, Dr. Shor was also responsible for authoring regulatory documents including the non-clinical pharmacology section for the Biological License Application (BLA) of a late stage ADC. Dr. Shor received a Ph.D. in Molecular and Cell Biology at the State University of New York and performed a postdoctoral fellowship in the Inflammation Research team at Johnson & Johnson Pharmaceutical R&D prior to joining Pfizer.
Dr. Shor commented: “I am delighted to join Immune at this important time as bertilimumab is advancing through the clinic and other exciting programs are coming on-line. The strength of science across immunology and oncology programs at Immune is impressive.” Dr. Shor continued, “I also see potential for Immune’s nanotechnology delivery platform for the effective treatment of diverse diseases including cancer. This provides a remarkable opportunity to play a major role in building an organization that is improving lives and outcomes in patients with autoimmune diseases and cancer.”
Immune recently hosted its first R&D day on September 8, 2015 at the Alexandria Center for Life Science in New York City. The Immune R&D day focused on the company pipeline in Precision Immuno-Therapy for Inflammatory Diseases and Cancer and featured several keynote speakers:
-Robert Goldberg, PhD presented on the importance of Precision Medicine to create value for patients and for the healthcare system.
-Yaron Ilan, MD – Chairman of Medicine, Professor of Gastro-Enterology and Liver Diseases at Hadassah Hospital, Jerusalem, IL, presented the role of eotaxin-1 as a key regulator of Immuno-Inflammation and the clinical potential of bertilimumab.
-Neil Korman, MD- Chairman of Dermatology, Case Western School of Medicine, Cleveland, OH presented the role of eotaxin-1 in Dermatology and the clinical potential of bertilimumab.
-Dr. Boris Shor, Immune’s Executive Director, R&D and Dr. Zahra Shahrockh, Chief Development Officer, STC biologics presented the company development plans for NanomAbs, for the targeted delivery of cancer drugs.
Dr. Daniel Teper, Immune’s CEO presented at the Rodman and Renshaw’s 17th Annual Global Investment Conference on Thursday, September 10th, 2015 at the St Regis Hotel.
A Webcast is accessible for the next 90 days at www.immunepharmaceuticals.com.
Immune also published the following list of recent accomplishments:
-Immune Pharmaceuticals secures financings of up to $21.5 million in gross proceeds from institutional investors
-Immune Initiates Phase II clinical trials with Bertilimumab in Ulcerative Colitis and Bullous Pemphigoid
-Immune expands immuno-dermatology development portfolio with topical nano-formulated Cyclosporine A
-Immune announced a partnership with STC Biologics for the development of an HER-2 targeted NanomAb towards the submission of Investigational New Drug (IND) application to the U.S. FDA
-Immune Pharmaceuticals Signs License & Research Agreement for AmiKet™ Nano
Immune also published the list of upcoming milestones and 2015 priorities:
-Ongoing patient enrollment process for Phase II in Bullous Pemphigoid (BP) and Ulcerative Colitis (UC) with Bertilimumab
-Top line results and Orphan Designation for Bertilimumab
in BP
-Continuing partnering activities of non-core assets with focus on Amiket
-Submission of Investigational New Drug (IND) application to the U.S. FDA for Bertilimumab in multiple indications
Recently, Vista Partners initiated coverage on Immune Pharmaceuticals Inc. (NasdaqCM: IMNP); with a twelve-month price target of $6.00. To download a FREE copy of the Immune Pharmaceuticals Inc. (NasdaqCM: IMNP) research report, please visit http://www.vistapglobal.com and click the “Download Research” icon to gain access to the report.
The post Are you Aware of Immune Pharmaceuticals (IMNP) Recent Activites, Progress & Future Milestones? appeared first on Vista Partners.